---
title: "U.S. Stock Market News | Weight-loss drug Zepbound expected to be approved in Japan next year, Eli Lilly up more than 1%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/216588859.md"
description: "On Friday, Eli Lilly's stock price fluctuated upwards, rising by 1.18% to $921.435 at the time of publication. On the news front, Eli Lilly's CEO stated on Friday that the weight loss drug Zepbound is expected to be approved in Japan next year"
datetime: "2024-10-11T15:01:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/216588859.md)
  - [en](https://longbridge.com/en/news/216588859.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/216588859.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/216588859.md) | [English](https://longbridge.com/en/news/216588859.md)


# U.S. Stock Market News | Weight-loss drug Zepbound expected to be approved in Japan next year, Eli Lilly up more than 1%

According to the Smart Finance app, on Friday, Eli Lilly (LLY.US) stock price fluctuated upwards, rising by 1.18% to $921.435 at the time of publication. On the news front, Eli Lilly's CEO stated on Friday that the weight-loss drug Zepbound is expected to be approved in Japan next year

### 相關股票

- [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md)

## 相關資訊與研究

- [British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks](https://longbridge.com/zh-HK/news/281263193.md)
- [Eli Lilly just delivered fantastic news to investors](https://longbridge.com/zh-HK/news/269703566.md)
- [5 Simple ETFs to Buy With $1,000 and Hold for a Lifetime](https://longbridge.com/zh-HK/news/281345615.md)
- [BUZZ-Rosenblatt says finding partner for Snap's smart glasses unit tough](https://longbridge.com/zh-HK/news/281357569.md)
- [BUZZ-Street View: Nike's turnaround remains work in progress](https://longbridge.com/zh-HK/news/281331333.md)